PureTech Health plc (LON:PRTC - Get Free Report) insider Bharatt Chowrira purchased 167,739 shares of PureTech Health stock in a transaction dated Thursday, July 3rd. The stock was acquired at an average price of GBX 1 ($0.01) per share, with a total value of £1,677.39 ($2,289.95).
PureTech Health Price Performance
LON PRTC traded up GBX 2.60 ($0.04) during trading hours on Friday, reaching GBX 129.40 ($1.77). The company's stock had a trading volume of 162,803 shares, compared to its average volume of 745,887. PureTech Health plc has a 1-year low of GBX 100.40 ($1.37) and a 1-year high of GBX 192 ($2.62). The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The company's 50-day moving average is GBX 131.44 and its two-hundred day moving average is GBX 136.57. The firm has a market capitalization of £388.69 million, a price-to-earnings ratio of -5.31 and a beta of 1.02.
PureTech Health Company Profile
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
